Denis Soulières
Chuzhou University(CN)Centre Hospitalier de l’Université de Montréal(CA)Université de Montréal(CA)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)3,317 cited
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,087 cited
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,654 cited
- → Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck(2003)807 cited
- → Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial(2020)728 cited